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ABSTRACT
Bronchioalveolar Carcinoma in Jefferson and McCracken Counties Kentucky: Gender
Differences in Survival
by
Jasneet Aneja

Bronchioalveolar carcinoma (BAC), a rare lung cancer, is more common in women, has a high
proportion of non-smokers, and better survival, especially in women, than other lung cancers.
Study subjects were 83 BAC patients from two Kentucky counties. Mean survival differences
were compared by selected variables. The results showed better survival for females (6.5 years)
than males (3.0 years, p-value 0.02); for urban (4.3 years) compared to rural residents (2.6 years,
p-value 0.04); and for females with history of hysterectomy (5.1 years) compared to females
without such history (3.3 years, p-value 0.02); the last finding supports a hormonal role in
survival. Study results support the previous findings of a female survival advantage in BAC.
Additional research is needed to determine reasons for this female survival advantage.
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CHAPTER 1
INTRODUCTION AND OBJECTIVES
Introduction
Lung cancer is the leading cause of cancer mortality for both men and women in the
United States, accounting for 13% of all new cases and 29% of all cancer deaths. In 2006, there
will be over 174,470 cases and 162,460 deaths (Jemal et al., 2006). The incidence is declining in
men from a high of 102 cases per 100,000 in 1984 to 62.3 cases per 100,000 in 2000; whereas
the rates have just begun to stabilize in women after years of steady increase. In stark contrast,
Kentucky’s lung cancer incidence is still increasing. Kentucky has one of the highest incidence
rates for lung cancer in the nation; the incidence for the year 2000 was 97.5 cases per 100,000
(American Cancer Society, Cancer Statistics 2004).
Lung cancer is broadly divided into non-small cell carcinomas (75%-80%) and small cell
carcinoma (20%-25%). Non-small cell lung carcinoma (NSCLC) is further divided into the
following histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell
undifferentiated carcinoma. Historically, squamous cell carcinoma was the most common
histologic type accounting for almost 70% of NSCLC (as cited in Read, Page, Tierney, Piccirillo,
& Govindan, 2004). However, for the past 2 decades there has been a steady increase in the
incidence of adenocarcinoma and at the same time a decrease in squamous cell carcinoma (Field
et al., 2004; Read et al.).
A rise in bronchioalveolar carcinoma (BAC), a histologic subtype of adenocarcinoma, is
thought to be the major reason for the increased incidence of adenocarcinoma (Barsky, Cameron,
Osann, Tomita, & Holmes, 1994). The reasons for this increase are not clearly understood.
Various authors (e.g. Auerbach & Garfinkle, 1991; Levi, Franceschi, La Vecchia, Randimibison,
9

& Te, 1997; Valaitis, Warren, & Gamble, 1981; Zell, Ou, Zigas, & Anton-Culver, 2005) have
attributed this shift to changes in the rate and type of cigarette smoking, changes in exposure to
new environmental carcinogens, and changes in the criteria for histopathological diagnosis of
lung cancer.
Another possible reason for an increase in the number of BAC patients may be the
increase in female lung cancer patients over the past 50 years. BAC, contrary to other types of
lung cancers, has a female predilection. Therefore, an increase in the overall number of female
lung cancer patients accompanied by a decrease in male patients may have lead to an increased
incidence of BAC and a decrease in squamous cell carcinoma, which is much more common in
men than women (Read et al., 2004).

Objectives
A series of patients with BAC from hospital-based cancer registries located at Jefferson
County and McCracken County, Kentucky from 1988-2005 was selected. They were selected for
another study evaluating occupational and environmental cancer risk in Kentucky (The Kentucky
Lung Cancer project, Aldrich, 2006). In that study, the BAC cases from 1996-2005 were
designated to represent the non-smoking lung cancer risk, an attempt to identify the
environmental portion of the overall lung cancer risk. Those cases were then provided for
analysis in this thesis. The objectives of this study are:
1. To determine overall survival and survival differences for this series of BAC cases by
gender, age, residential location, smoking history, and family history of lung cancer.
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2. To assess if the reclassification of bronchioalveolar carcinoma by the World Health
Organization (WHO) in 1999 has impacted either survival or the proportion of female
patients in this series.
3. To compare the results of this series of BAC cases with the Kentucky Cancer Registry
(KCR) database and the national Surveillance, Epidemiology, and End Results (SEER)
database.
4. To explore whether there may be evidence to indicate that hormone estrogen
events/levels affect the length of survival in this series of female BAC patients.
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CHAPTER 2
BACKGROUND AND SIGNIFICANCE
Historical Perspective
In 1876, French clinical microscopist Louis Malassez first reported the gross and
microscopic description of a newly discovered type of malignant lung tumor that had occurred in
a 47-year-old woman. It was a carcinoma with distinct alveolar distribution that presented with
numerous fused tumor nodules, central necrosis, and preserved alveolar structure of the lung.
The cells of the tumor were well differentiated and spread along the alveoli with little stromal
reaction (Liebow, 1960).
During the early part of 20th century numerous prominent pulmonary physicians
attempted to distinguish the above mentioned lung tumor from other lung cancers. In 1960
Averill Liebow, professor of pathology at the Yale University School of Medicine, named this
tumor bronchioalveolar carcinoma. He defined it as a generally well differentiated
adenocarcinoma located primarily in the periphery of the lung well beyond a grossly
recognizable bronchus with the walls of the distal air spaces acting as supporting stroma for the
neoplastic cells and a tendency to spread chiefly within the confines of the lung by aerogenous
and lymphatic routes (Liebow, 1960). Liebow’s definition was accepted by the WHO and the
American Joint Committee on Cancer (AJCC) in 1967 (as cited in Laskin, Sandler, & Johnson,
2005).

Histology
The most recent WHO definition states that BAC is a lung adenocarcinoma that is
diagnosed in the absence of a primary adenocarcinoma at any other site, has no central
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bronchogenic source, is peripheral in location, has an intact pulmonary interstitium, and exhibits
malignant cells growing along the alveolar septae (as cited in Dumont et al.,1998). The key
feature is the preservation of the underlying lung morphology.
BAC shares some features with other lung adenocarcinomas and most of the time two
histological patterns are seen together. Pure BAC represents only about 3%-4% of cases of
adenocarcinomas. Adenocarcinomas with some BAC features are much more common and
include cancers that are predominantly BAC with a small focus of invasive disease (Castro,
Coffey, Medeiros, & Cagle, 2001).
The histopathological classification of BAC includes three subtypes (Lamb 1984; Madri
& Carter, 1984):
Mucinous: Mucinous BACs arise from the bronchial mucous cells and are characterized
by tall columnar cells, with a pale apical cytoplasm that are PAS positive. The nuclei are bland in
appearance with occasional nuclear clefts. The tumor cells contain central to apical cytoplasmic
vacuoles and abundant microvilli.
Non Mucinous: Non-mucinous BACs arise along the alveolar walls; they exhibit some
degree of focal interstitial thickening and lymphocytic infiltration. The malignant cells
themselves are cuboidal or columnar with apical snouting and central nuclei. Multinucleated
giant cells and eosinophlic nuclear inclusions may be present. There is a predominance of Clara
cells.
Sclerotic: This type of BAC appears similar to non-mucinous at light microscopic and
ultra structural levels and presents with areas of sclerosis. Sclerotic BACs account for a
considerable number of scar carcinomas. Various authors disagree on the origin of the scar.
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There is debate whether the scar is because of the carcinoma or if the malignancy develops
around scar tissue (Madri & Carter, 1984; Ochs, Katz, Edmunds, Miller, & Epstein, 1982).
Several studies have reported high inter-observer variability especially with regards to
BAC subtype (e.g., Dumont et al., 1998; Madri & Carter, 1984). Available literature suggests
that mucinous BACs account for 21%, non mucinous for 68%, and sclerotic for 10% of all BAC
cases (Madri & Carter, 1984). Non-mucinous BACs have better prognosis as they tend to be
more localized and present with a lower tendency of bronchogenic spread (Dumont et al.).
A 21-year retrospective autopsy study conducted in Glasgow concluded that
bronchioalveolar carcinoma is a valid classification that describes a specific disease entity.
Furthermore, they established that in pathological terms it represents a heterogeneous population
of tumors that are amenable to surgical resection at initial stages (as cited in Barsky et al., 1994).

Clinical Features
BAC presents as a slow growing multifocal disease with intrathoracic metastasis, slow
rate of growth and progression, longer median survival rates, and a higher prevalence in women
compared to men (Grover & Piantadosi, 1989). When the tumor is localized to a single
hemithorax, the patient may be asymptomatic. More than 50% of the patients are asymptomatic.
When symptoms are present, the most frequent symptoms are coughing (35%), chest pain (25%),
dyspnea (15%), weight loss (13%), fever (8%), and hemoptysis (11%). Distant metastases are
hardly ever present. In the rare instance of distant metastases the symptoms depend on the site of
metastasis (as cited in Axiotis & Jennings, 1988; Barkley & Green, 1996; Edgerton, Rao, Takita,
& Vincent, 1981; Lee & Kim 1997).
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Bronchorrhea (productive cough with white mucoid or watery expectoration), once
considered the clinical hallmark of this disease, is now viewed as an unusual and late
manifestation seen only in the diffuse form of the carcinoma. The prevalence of bronchorrhea
was reported between 27%-35% in 1953, whereas a later study reports it to be 5% (Edgerton et
al., 1981)
Rare symptoms reported are pulmonary hypertension, pneumothorax, or even pericardial
temponade (Singh, Nath, Pinkard, & Alexander, 1994). Late stages (III or IV) of BAC are
associated with a greater likelihood of symptoms than earlier stages. Therefore, when symptoms
are present the prognosis is poor. BAC shows poor response to chemotherapy with an average
survival of 9 months. Traditionally, only symptomatic patients with late stage disease are
considered for chemotherapy and earlier stages are treated with more aggressive approaches such
as surgical resection. This can account for poor survival of patients receiving chemotherapy
(Ebright et al., 2002).

Epidemiology

Incidence and Prevalence
Fifty years ago BAC was a rarely diagnosed neoplasm accounting for less than 3% of all
lung cancer cases in the United States, with an average age adjusted incidence of 1.5 cases per
100,000 (Laskin et al., 2005). BAC has increased from 5% cases in 1955, 9% in 1978, 20% in
1985, and to 24% of all NSCLCs in 1990 (Fig.1). The average age adjusted incidence rose from
6.5 in 1987 to 10 cases per 100,000 in 2004 (Field et al., 2005). Over the past 50 years there has
been a steady increase in BAC diagnosis along with a steady decrease in the frequency of other

15

histotypes. Incidence of BAC has increased because of an increase in number of female cases, in
whom the cancer is more common (65% adenocarcinomas vs. 35% other types) and a shift in
male cases from squamous cell carcinomas to adenocarcinomas (Auerbach & Garfinkle, 1991).
Some authors report the increase in adenocarcinoma cases is solely because of an
increase in the number of BAC cases (e.g. Jemal et al., 2006; Travis, Garg, & Franklin, 2005),
while other studies report an increase in adenocarcinoma cases but no change in pattern of BAC
incidence (as cited in Mirtcheva, Vasquez, Yankelevitz, & Henschke, 2005).

% BAC Cases of all the NSCLCs
30
25
20
% BCA 15
10
5
0
1955

1978

1985

1990

Year

Figure 1. Percentage of BAC Cases by Year.

The mean age-at-diagnosis of BAC patients is lower than that for any other lung cancer
type (67 yrs vs. 69 yrs) (Leno, Doyal, & Edelman, 2005). According to Liu, Chen, Huang, and
Perng (2000), the average age-at-diagnosis of BAC patients is 66 years with women (63 yrs)
being younger than men (68 yrs). The 1-year (65% vs. 42%) as well as 5-year (35% vs. 15%)
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survival for BAC is much better than for all other types of lung cancer grouped together (as cited
in Jemal et al., 2006; Liu et al.).

Reclassification and Its Impact on Survival
BAC was reclassified at the WHO conference for classification of lung tumors on May
28th 1999. It was the third time the definition of BAC was altered. The earlier two events had
been 1967 and 1981 (World Health Organization, 1999). Periodic reclassification has lead to
increased recognition that may account for a part of the increase in reported incidence of this
cancer. After the revised definition in 1999, the mean overall survival of BAC patients has
increased as compared to patients diagnosed before 1999, whereas no significant difference was
reported for non-BAC NSCLC patients (Janssen & Coebergh, 2003; Zell et al., 2005). The lack
of survival benefit for non-BAC NSCLC patients diagnosed after May 1999 suggests that this
positive trend in BAC survival cannot be attributed to an overall improvement in lung cancer
management during this time period (Laskin et al., 2005).
According to Zell et al. (2005), changes in the epidemiology of BAC may be attributed
solely to the re-classification in 1999. Since 1999, there have been more women patients (63% vs.
55%) and more non-smokers (27% vs. 18%) than before. The survival advantage is reported
more in patients with localized disease than in patients with metastatic tumor. They further
reported that 41% of patients diagnosed with metastatic BAC before May 1999 died because of
the cancer, whereas in cases of localized BAC, 31% of the patients died of the cancer. On the
other hand, in patients diagnosed after 1999, 70% with metastatic tumor died because of BAC
and less than 10% of patients with localized tumor died because of the cancer indicating that a
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survival advantage existed only for localized lesions. The proportion of patients who presented
with metastasis was much smaller after 1999 (35% vs. 59%) than before (Laskin, 2004).
Corroborative findings by various authors (e.g. Janssen & Coebergh, 2003; Laskin et al.,
2005) indicate that after the reclassification in 1999. BAC presents with a higher proportion of
females, more never smokers, earlier stage at presentation, and improved survival compared to
other NSCLC and BAC patients before reclassification. As a consequence of these significant
changes in epidemiology of BAC, the recent 2005 WHO classification retained all the changes
suggested in the 1999 definition (as cited in Zell et al., 2005).
On the other hand, certain authors like Castro et al. (2001) report a 5% discordance rate
between the original diagnosis and review diagnosis after reclassification in 1999 when they rediagnosed the cases by applying the 1999 criteria to earlier cases. Their findings suggested that
reclassification alone cannot attribute for all the increase in incidence and survival. Their
research consisted of comparing retrospective studies based on autopsy reports to those based on
hospital diagnosis. They recognized that the incidence is much higher in the autopsy reports
indicating the number of BAC cases that remained un-diagnosed and un-reported is significant.
This is in contrast to findings reported by other studies who reclassified cases diagnosed
before 1999 with the post 1999 criteria and found that 41% of their prior BAC cases were other
adenocarcinomas and not BAC according to the new definition (as cited in Laskin, 2004). Travis
et al. (2005), suggest popularity of screening with low emission helical CT scan as a contributor
to the increased identification of clinical cases because of discovery of many relatively smaller
tumors that otherwise were difficult to diagnose. This may very well be one of the more
important reasons for the early diagnosis and the subsequent increase in survival for true cases of
BAC.
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Etiology and Risk Factors
The exact etiology of BAC has been aggressively debated (Barkley & Green 1996;
Barsky et al., 1994; Dumont et al., 1998; Madri & Carter, 1984). The true burden of smoking as
an etiological agent has been controversial (as cited in Laskin, 2004). Various factors implicated
as possible etiological agents are listed below.
Smoking: It is suggested that the association between BAC and smoking is the weakest
for all lung cancer subtypes. Almost 33% of patients with BAC are non-smokers compared to
5% of all other lung cancer patients grouped together. Furthermore, BAC patients who are
smokers smoke less (34 vs. 42 pack/years) than patients with other types of lung cancers
(Auerbach & Garfinkle, 1997). On the other hand, various studies have shown that smoking low
tar filtered cigarettes increases the risk of developing adenocarcinomas like BAC. Filters remove
larger particles in cigarette smoke, thus reducing deposition of those particles in central airways
but not the smaller peripheral airways. This could lead to a reduction in incidence of the
squamous cell carcinomas that develop centrally, but not of BAC that primarily occurs in
peripheral areas of the lung (Charloux et al., 1997). Smoking cessation also does not seem to
have much of an impact on reduction of risk (as cited in Auerbach & Garfinkle; Radzikowska,
Glaz, & Roszkowski, 2002). Environmental tobacco smoke similarly presents with a weaker
association as compared to the rest of the lung cancers (Edgerton et al., 1981). Some authors
(Leno et al., 2005; Read et al., 2004) fiercely argue that the burden of incidence can be solely
placed on smoking. Collectively these studies identify smoking as one of the etiological factors
for BAC but it is likely not the only cause. More research needs to be done to evaluate the extent
of contribution of cigarette smoking as an etiologic factor for BAC.
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Family history: Patients with positive family history for lung cancer are reported to be at
a 2.5 times higher risk for developing BAC than patients with no family history. Patients with a
parent diagnosed with lung cancer have four times the risk and those with a sibling who has lung
cancer are at twice the risk of developing BAC than patients with no family history (Cote, Kardia,
Wenzlaff, Ruckdeschel, & Schwartz, 2005; McDoniels-Silvers, Nimri, & Stoner, 2002). This
risk is consistent among all histological sub-types.
Viruses: A characteristic diffuse multicentric presentation of the disease has led some
investigators to suggest a viral etiological agent. Viral etiology was first suggested in 1940s
because similarity both at the histological and gross levels of BAC with Jaagsieke’s disease
found in sheep. Also known as sheep pulmonary adenomatosis, Jaagsieke’s disease is caused by
a retrovirus. Retrovirus B and D are suspected to cause BAC in humans (Page, Green, &
Lackland, 2000). Because there has never been a case of animal to human transmission and
farmers who rear sheep are not reported to be at higher risk of developing BAC, the association
between retrovirus and BAC has not been clearly established. Furthermore, no viral component
has ever been isolated from BAC tumors. Page et al. further report another virus, the Human
Papillomavirus (HPV) types 16 and 18, as an etiological agent. HPV is said to cause BAC in
women more than men (OR 10.2). Auerbach and Garfinkle (1997) report that a decrease in
adenocarcinomas and an increase in peripheral BAC can be a consequence of HPV. Much
research needs to be conducted in this area before anything can be cited with certainty.
Other causes: BAC may also arise in lung parenchyma previously destroyed by
tuberculosis, infection, or pulmonary fibrosis of any kind (Madri & Carter, 1984; Ochs et al.,
1982; Singh et al., 1994). There have been reports of increased risk of BAC in people working in
the construction industry, wood and paper mills, motor freights and sugarcane farming
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(Rothschild & Mulvey, 1982). Motor freight industry workers show as much as a four-fold
increase in risk of developing BAC as compared to general population (as cited in Morton &
Treyve, 1982). According to Madri and Carter (1984), these exposures cause epithelial
proliferation that subsequently leads to malignant transformation of healthy tissue surrounding
these areas of proliferation.
Other risk factors implicated are radon and asbestos. Radon was first identified as a risk
factor among Uranium miners. It is the most commonly found household carcinogen. Radon
decay accounts for 95% of natural radiation exposure of bronchial epithelium. The percentage of
BAC cases attributed to radon exposure is between 1-10%. Radon has the same kind of
association with BAC as with other lung cancers (as cited in Read et al., 2004).
Asbestos was the first recognized occupational risk factor for lung cancer. The risk
presented by asbestos for developing BAC is similar to the risk for developing other histological
subtypes of lung cancer (Radzikowska et al., 2002).
In China, where the rate of lung cancer in non-smoking women is one of the highest in
the world, indoor pollution because of coal burning has been implicated in the genesis of lung
cancer (as cited in Wu, Henderson, Thomas, & Mack, 1986).

Female BAC Risk
The incidence of lung cancer in men plateaued in 1980s and has been steady since.
However, the increase in cases of lung cancer in women over the past 50 years has been
staggering giving it the name of a “Contemporary Epidemic” (as cited in Patel, Bach, & Kris,
1999). In 1950 women represented less than 10% of lung cancer patients, while in 1990 35% of
cases were female (as cited in Leno et al., 2005). The number of cases in women has gone up by
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more than 500% in the last 50 years, surpassing breast cancer prevalence since 1984 and by
20,000 cases annually at present. Although lung cancer mortality for men has been steady for the
last 15 years, it is projected that the rates for women have only recently begun to stabilize and
are expected to show this same trend until 2010 after which they may begin to decrease (Jemal et
al., 2006; Radzikowska et al., 2002). Figure 2 shows lung cancer mortality for both sexes from
1989-2003. There were 88,975 male lung cancer patient deaths in 1989 vs. 89,908 deaths in 2003
whereas in case of female patients there were 48,042 deaths in 1989 vs. 68,908 in 2003 (Jemal et
al.).

Male and female lung cancer moratlity (1989-2003)

Number of deaths

100,000
80,000
60,000

male

40,000

female

20,000
0
1989 1991 1993 1995 1997 1999 2001 2003
Year

Figure 2. Lung Cancer Mortality by Gender

The rise in overall number of cases of BAC is in part be contributed by the rise in the
number of female lung cancer cases. Among all the lung cancer types, BAC has the highest
proportion of female non-smokers. Because of its relatively weak association with smoking as
compared to other histotypes, an increase in BAC as a consequence of female smoker cohorts
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crossing the risk threshold can only explain a small proportion of BAC increase (Clayton 1998;
Laskin, 2004; Leno et al., 2005).
Although smoking prevalence has decreased in men by half in the last 40 years, it has
decreased only by 25% in women in the same period. Almost a quarter of adult females in the
United States are smokers and most of them (85%) started smoking as teenagers (as cited in
Leno et al., 2005). It is difficult to assess the true association of smoking as an etiological agent
because of a high prevalence of smoking and under-reported environmental smoking (Page et al.,
2000). To reduce the effect of smoking as a confounder, Kit et al. (as cited in Page et al.)
conducted a study analyzing lung cancer in China and Hong Kong where the prevalence of
smoking in women is less than 5%. Per their results, almost 90% of lung cancer cases in
mainland China and up to 62% in Hong Kong presented as non-smokers. More than 60% of
these cases were adenocarcinomas and BAC contributed the biggest fraction of the
adenocarcinoma cases (Page et al.). More research needs to be done to evaluate the causes of
increased incidence of BAC with particular emphasis on women.
The survival rates and prognosis for BAC is better in women as compared to men. This
has been attributed in part to the fact that women have generally presented younger at the time of
diagnosis, but this cannot account for all the cases (Devesa, Bray, Vizcaino, & Parkin 2005; Page,
et al., 2000). Emerging evidence indicates that there are differences in the pathogenesis and
susceptibility to lung cancer in women. Researchers also believe that women are more
susceptible to the carcinogenic effects of smoking than men (Auerbach & Garfinkle, 1991;
Radzikowska et al., 2002; Travis et al., 2005).
Possible Reasons for Differences in Women. The rise in lung cancer-related mortality
among women accompanied by a decrease in men has significantly altered the male/female ratio
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of lung cancer. While much of this altered epidemiology can be attributed to changing patterns of
tobacco use, it is becoming increasingly apparent that relative risks (RRs) of specific types of
lung cancer, the relationship between smoking and lung cancer, and the response to therapy may
not be the same for both sexes (Page et al., 2000; Zang & Wynder, 1996). BAC is a stronger
indicator of such differences than other types of lung cancers. There are several differences in
men and women with respect to incidence and prevalence of BAC that are of growing
importance and may impact diagnosis, treatment, and outcome (Leno et al., 2005).
Higher risk to carcinogenic effects of smoking: Several studies have shown women to be
at greater risk than men to carcinogenic effects of smoking. Some studies reported that when
compared on the basis of pack years smoked women develop BAC earlier than men (31 vs. 39
packs/years) (as cited in Radzikowska et al., 2002). The reason attributed for this increased
susceptibility is the smaller lung volume and body size on average in women compared to men
(Devesa et al., 2005). Women are also reported to have higher levels of tobacco-related DNA
adducts and DNA transversions than men as a response to carcinogens in cigarettes despite lower
exposure levels (as cited in Page et al., 2000). These DNA adducts hamper the DNA repair
capacity, therefore, making the lung cells more susceptible to malignant transformation. An
increase in BAC is reported to be because of increased smoking of low-tar cigarettes by women
that are suspected to cause more DNA transversions and peripheral lung cancers (McDonielsSilvers et al., 2002; Page et al.). To support these findings additional investigation is required.
Growth factors: Certain growth factors have been shown to stimulate the growth of
neoplastic cells in the lung. A receptor for autocrine growth factor called GRPR (gastric
releasing peptide receptor) has been identified in various lung cancers, especially BAC. The
GRPR gene is on the X chromosome and escapes X inactivation. This gene is expressed more
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frequently in female non-smokers than male patients and female smokers and can be activated
early in response to tobacco smoke. The presence of these growth factors may account for the
younger age at diagnosis of female BAC patients (Didkowska, Manczuk, McNeill, Powles, &
Zatonski, 2005; McDoniels-Silvers et al., 2002).
Hormonal influences: More obvious differences between men and women are hormonal.
An estrogen driven environment has been recognized in the pathogenesis of breast, endometrial,
and ovarian cancers. The reason for the greater predilection of women to the effects of
carcinogens of lung cancer may be because of estrogen signaling (Devesa et al., 2005).
Gender and Survival. Over the past 50 years most of the research regarding lung cancer
has been done with male patients. Most of the treatment modalities and screening procedures
such as spiral CT scan are used because of their documented success in men (Travis et al., 2005).
Only recently the differences between men and women with respect to lung cancer and more
specifically BAC have been properly documented and considered (McDoniels-Silvers et al.,
2002; Page et al., 2000).
Women respond better than men to different treatment modalities like chemotherapy and
surgical resection .This association is more pronounced in 5-year and longer survival rates.
Increased survival in women compared to men is consistent across all age groups and all stages
of BAC. Other histological types of adenocarcinoma also show a survival advantage for women
compared to men but this trend is much more pronounced in BAC patients (Leno et al., 2005).
The survival advantage of female BAC patients could be because women present younger
than men at the time of diagnosis and are more physically resilient than men because of their
younger age. Differences in the hormonal milieu in men and women are also suspected to
contribute to differences in survival between male and female patients with BAC.
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The role of estrogen in lung cancer is not very clearly understood and it remains very
controversial (as cited in Falk et al., 1992; Ishibashi et al., 2005; Leno et al., 2005). Some authors
(as cited in Leno et al.) suspect estrogen acts as a direct carcinogen via the formation of DNA
adducts. Others (Ishibashi et al.) implicate an indirect role in activation of growth factor genes
(e.g. epidermal growth factor) or by acting on receptors (e.g. GRPR). There are conflicting data
regarding the prognosis of lung tumors that have estrogen receptors. Lung parenchyma has
abundant estrogen receptors. Authors report 0% to 96% estrogen receptor expression in lung
cancer (Ishibashi et al.). Stabile et al. (as cited in Page et al., 2000) reported a 17-fold increase in
proliferation of lung cancer cells as opposed to a 4-fold increase in normal lung parenchyma
cells when exposed to estradiol. These findings suggest an increased responsiveness of malignant
lung cells to estrogen. According to Yang et al. (as cited in Page et al.), 5-year survival of female
patients with active estrogen receptors is significantly lower (9% vs. 70%) than female patients
with no estrogen receptors. Another study showed a positive prognosis with respect to male
patients with active estrogen receptors as compared to women
The possible association of hormone replacement therapy (HRT) with survival in patients
with lung cancer is also a very controversial issue. Adami, Persson, Hooover, Schairer, and
Berqkvist (1989) have shown an increased risk (OR 1.7) of lung cancer in women receiving HRT.
A case-control study from Texas on the other hand showed a reduced risk of lung cancer (OR
0.6) and an increased survival time in patients receiving HRT (Schabath, Wu, & VassilopoulouSellin, 2005). Early menopause, indicative of decreased levels of estrogen, is associated with a
decreased risk (OR 0.3) of BAC (as cited in Minn et al., 2005). Certain studies report that
premenopausal women presented with later stages of lung cancer and had higher mortality than
postmenopausal women (as cited by Read et al., 2004).
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There has been only limited research conducted to evaluate the above mentioned effects
and only a very few of those stratified their results according to histological sub-types (Minn et
al., 2005). Therefore, more research needs to be conducted with respect to survival advantage
provided by HRT before any conclusions can be drawn.
Even with the deficiencies in BAC research it can be stated with certainty that the
incidence, prevalence, and mortality of the disease is different for men and women implying that
the way the disease is treated in men and women should also be different. A change in the
treatment modality by taking into account the possible effects of estrogen on cancer cells can
change the way we look at the survival of women with BAC (Falk et al., 1992).
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CHAPTER 3
METHODS
Study Design
This descriptive study analyzed 83 patients with BAC from two geographically and
demographically distinct locations in Kentucky. One in the city of Louisville, Jefferson County,
beale code 2; classified as medium metro and the other in Paducah, McCracken County, beale
code 5; classified as non-metro and non-adjacent to metro (The US Census Bureau, American
Community Survey Data Profile, 2003). The data were collected from three cancer registries,
two located at Louisville and the other located at Paducah. Data analysis was performed in order
to obtain a description of the study group. Then, a comparison was made with the state and
national data sources to see if the traits seen in the study group were consistent with the former.
The source for the state data was the Kentucky Cancer Registry (KCR) dataset from 1996-2000
(issued in 2001) extracted October 1, 2002. The SEER Cancer Incidence Public Use Database
1973-1998 (issued in April 2001) was used to analyze the nationwide data. Lung tumors (site
code C33, C34) were extracted and out of those the bronchioalveolar carcinomas (histology code
8250-8254) were used for comparison with the study group (ICD-9-CM: International
Classification of Diseases, 1997).

Data Source
This research was done alongside another initiative the ‘Kentucky Lung Cancer Project’
funded by the State of Kentucky and undertaken by the University of Kentucky, Lexington, KY.
The primary objective of ‘The Kentucky Lung Cancer Project’ was to find possible cancer
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clusters located near major petrochemical plants in the regions of McCracken, Jefferson, and
Boyd Counties, KY.
Data were extracted as hospital records and discharge sheets of lung cancer patients
diagnosed from 1988-2005. The source data were stored either as microfiche files or original
(paper) hospital records. Prior to data collection, requests were placed with the registries for
records of patients with BAC or mesothelioma. The registries at Louisville provided abstracts of
the patients’ hospital records and complete records were provided only on further request for
specific patients. On the other hand, the registry at Paducah, KY provided excerpts from the
hospital records with all relevant information with respect to the variables of interest.
Hospital registrars contact patients annually and review state death certificates
periodically to identify deceased registry patients. The last day of follow-up for this study group
was either the date of last contact with the patient or the date of death.

Study Sample
The initial study group for this thesis consisted of 88 BAC patients. Twenty-five of these
patients were recruited from University of Louisville cancer registry, 30 from Norton hospital
registry, and 33 from Western Baptist hospital registry. Five of the original patients were
excluded (3 cases from Norton registry and one each from the University of Louisville registry
and the Western Baptist registry each). The reasons for exclusion were wrong diagnosis,
incomplete records and lack of information on survival status. Demographic characteristics of
the study sample are given in Table 1.
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Data Management
The data were gathered and recorded in the form of Microsoft Excel spread sheets. The
selected variables were entered in the spread sheets after the data were collected. Quality control
was performed by the PI of the ‘Kentucky Lung Cancer Project’, Dr. Timothy Aldrich, in order
to minimize errors in data entry, retrieval, etc.

Variables of Interest
The variables taken under consideration were (i) gender, (ii) age at diagnosis, (iii) year of
diagnosis, (iv) survival status at the time of data collection, (v) smoking status, (vi) residential
location, and (vii) family history of lung cancer. Table 1 gives a detailed description of the
variables used for analysis. For the purpose of assessing the possible effect of estrogen on the
prognosis of BAC in women, three additional variables were analyzed for the female patients.
They were: (a) history of hysterectomy, (b) treatment with hormone replacement, and (c) history
of other types of hormone mediated female cancers such as cervical or breast cancers.

Statistical Analysis
The data was analyzed using the statistical software Statistical Software for Social
Sciences [SPSS®]. Descriptive statistics were conducted with the variables of interest and graphs
were drawn for selected variables. Independent sample t-test, ANOVA, Kaplan Meier survival,
and Cox-proportional hazard analyses were applied. Kaplan Meier survival analysis was also
used to plot survival curves. Statistical significance was assumed for a two-tailed p-value less
than 0.05. Confidence intervals and significance values were reported for the analysis. The study
sample and KCR and SEER datasets were analyzed independently.
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CHAPTER 4
RESULTS
Description of the Sample
The demographic characteristics of the study sample are presented in Table 1. The study
group consisted of 83 patients: 51 women and 32 men. Thirty-one percent of the patients were
non-smokers (n=26). Two races were represented out of which only 8.4% (n=7) of the patients
were African American and the rest were Caucasian. A total of 61.4% of the patients were from
Louisville registries (28.9% from University of Louisville and 32.5% from Norton hospital),
whereas 38.6% were from Western Baptist hospital at Paducah. Almost 29% of the patients
(n=24) were alive at the time of data collection, 61.4% (n=51) had died because of the cancer
itself, and 9.6% (n=8) had died because of other causes. The proportion of patients who had a
family history of lung cancer was 20% (n=17). More than half of the patients in the study sample
resided in urban areas (61.4%, n=51).
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Table 1.
Demographic Characteristics of the Study Sample
Variable
Gender

Number (n)

Percentage (%)

Male
Female
Univ of Louisville
Norton hospital
Western Baptist

32
51
24
27
32

38.6
61.4
28.9
32.5
38.6

Race

White
Black

76
7

91.6
08.4

Smoking

Smoker
Non-smoker
Alive
BAC deaths
Other cause deaths

57
26
24
51
08

68.7
31.3
28.9
62.4
09.6

Family History of lung cancer Present
Absent

17
66

20.5
79.5

Rural/Urban

Urban
Rural

51
32

61.4
38.6

Age

Younger than 65
Older than 65

30
53
83

35.4
64.6
100

Registry

Survival status

Total

The mean age-at-diagnosis for the cohort was 67 years (Table 2) with the youngest
patient being diagnosed at 38 years and the oldest at 85 years. Age-at-diagnosis cross tabulated
for variables of interest with 95% CI and p-value calculated using the t-test and ANOVA is
presented in Table 2. Men were younger than women at the time of diagnosis (64.7 yrs vs. 68.5
yrs, p-value =0.03) and smokers were diagnosed at younger ages than non-smokers (66 yrs vs. 68
yrs, not significant). African-American patients presented older than Caucasian although this was
not a significant finding. Patients who died of BAC were younger than the patients who died of
some other cause (67.5 yrs vs. 73.7 yrs, p-value=0.08). The patients in this study who had a
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family history of lung cancer were diagnosed at older ages than the patients with no family
history (70.8 yrs vs. 66 yrs), but this finding was not significant. Patients from Louisville
registries (urban area) were significantly younger at the time of diagnosis than patients from
Paducah (64.8 yrs vs. 70.6 yrs, p=0.02).
Table 2.
Age at Diagnosis with Reference to Variables of Interest
Variable

Mean(yrs)

95% Confidence interval (yrs)
Lower bound Upper bound

p-value

Gender

Male
Female

64.7
68.5

61.2
65.8

66.3
71.9

0.03

Race

White
Black

66.9
68.8

64.3
58.2

69.4
79.5

0.66

Smoking
Status

Smoker
Non-smoker

66.1
68.1

64.2
63.2

73.7
69.1

0.30

Location

Urban
Rural

64.8
70.6

61.4
67.5

68.2
73.7

0.02

Fam Hx

Present
Absent

70.7
66.1

65.3
63.3

76.1
68.8

0.13

Alive
Died of BAC
Died other cause
Overall Avg. age

63.8
67.5
73.7

58.5
64.4
68.1

69.1
70.5
79.3

Survival
status

0.08

67.1

Mean survival after diagnosis was 5.3 yrs (Table 3) ranging from 0.1 yrs to 16.2 yrs. The
mean follow-up time was comparable in alive and dead patients (4.3 yrs vs. 3.9 yrs). Kaplan
Meier survival analysis with Wilcoxan chi-square is presented in Table 3. Women survived
longer than men (6.5 yrs vs. 3.0 yrs, p-value 0.02), who were 5.2 times more likely to die of the
disease than women. Furthermore, 1-year survival for both genders was comparable (71% of
male patients vs. 76% of female patients) but 5-year survival was better for women (31% vs.
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16%).The survival curve highlighting the difference in cumulative survival between men and
women is shown in Figure 3. Non-smokers had longer average survival than smokers (4.2 vs.
3.4) but this difference was not significant on a 0.05 probability. Caucasian patients survived
longer than African American patients (5.1 vs. 4.0, not significant). Patients from urban areas
survived significantly longer than patients from rural areas (4.3 vs. 2.6, p value 0.04). Patients
who had a family history of lung cancer had shorter survival than those who had no history (3.0
vs. 3.8), although not significantly. Patients who died of causes other than the BAC lived longer
than patients who died because of the BAC (3.9 yrs vs. 2.3 yrs, p-value 0.04).
Table 3.
Mean Survival of Patients with Respect to Variables of Interest
Variable

Avg.
survival(yrs)

95% Confidence interval
Lower
Upper

Chisquare*

pvalue

Gender

Male
Female

3.0
6.5

2.2
4.6

3.8
8.4

5.2

0.02

Race

White
Black

5.1
4.0

3.8
2.6

6.5
5.8

0.5

0.48

Smoking
status

Smoker
Non

4.7
6.2

3.6
3.2

8.8
6.2

0.57

0.44

Location

Urban
Rural

5.7
3.5

4.1
2.3

7.4
4.7

1.5

0.04

Fam Hx

Present
Absent

3.9
5.3

2.3
3.9

5.4
6.8

1.1

0.90

Age

<65
>65
Overall
survival

6.2
3.7

3.9
2.8

8.5
4.5

1.4

0.001

5.3

3.9
6.6
* Wilcoxan Chi-square

.
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Survival Functions
sex

1.0

1
2
1-censored
2-censored

Cum Survival

0.8

0.6

0.4

0.2

0.0
0.0

5.0

10.0

15.0

20.0

yrs after Dx

Figure 3. Cumulative Survival Curve by Gender.
sex1: Male patients, sex 2: Female patients.
Survival curve plotted using Kaplan Meier life table programs

Comparisons Between Male and Female Patients
There were more female non-smokers (23 out of 27 non-smokes) than male, but smoking
did not have a significant effect on survival or the age-at-diagnosis for women. Gender specific
comparisons for survival and age-at-diagnosis are tabulated in Table 4. After stratifying for
location both men and women showed significant differences in survival and this difference was
more pronounced in men compared to women. In both genders, patients in the urban locations
survived longer than those in rural settings (6.9 yrs vs. 4.2 yrs for women, p-value 0.05 and 3.6
yrs vs. 2.4 yrs in men, p-value 0.03). Both men and women who had a family history of the
disease were diagnosed with the disease later than those who did not have a history of lung
cancer, with this difference being more pronounced in women as compared to men (66 yrs vs. 74
yrs in women and 64 yrs vs. 62 yrs in men). Both male and female patients with a family history
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of lung cancer had significantly shorter survival time than those with no history. This difference
was more pronounced in women (3.2 yrs vs. 7.2 yrs, p-value=0.06) compared to men (2.6 vs. 4.7,
p-value=0.08). To further assess the affect of age on survival time, age was dichotomized into
groups of patients who were younger than 65 at the time of diagnosis and those who were older.
Younger patients survived longer than the older patients and this effect was much more
pronounced in women (3.2 yrs vs. 7.2 yrs, p-value 0.01), men on the other hand showed no
significant differences.
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Table 4.
Gender Specific Comparisons for Survival and Age at Diagnosis
Variables ( n= number of
patients)

Survival
(yrs)

95% CI
(yrs)

pvalue

Age
(yrs)

95% CI
(yrs)

p-value

Smoker

Male (n=29)
Female(n=28)
Overall(n=57)

3.1
6.3
4.7

2.2 – 4.0
3.7 – 8.9
3.6 – 8.8

0.80

60.4
70.3
66.1

43 – 76
65 – 75
64 – 73

0.40

Non

Male (n=3)
Female(n=23)
Overall(26)

2.4
6.8
6.2

0.6 – 4.7
1.3 – 3.3
3.2 – 6.2

0.90

65.8
67.2
68.1

61 – 79
62 – 71
63 – 69

0.30

3.6
6.9
5.7

2.6 – 4.6
4.5 – 9.2
4.1 – 7.4

0.02

62.6
66.3
64.8

55 – 66
63 – 72
61 – 68

0.06

2.4
4.2
3.5

1.0 – 3.8
2.5 – 5.9
2.3 – 4.7

0.06

68.3
72.4
70.6

61 – 70
69 – 77
67 – 74

0.05

Urban

Male (n=18)
Female (n=33)
Overall(n=51)

Rural

Male (n=14)
Female (n=18)
Overall(n=32)

Fam Hx

Male (n=6)
Female(n=11)
Overall(n=17)

4.7
3.2
3.9

2.4 – 7.0
1.2 – 5.2
2.3 – 5.4

0.08

64.7
64.1
70.7

53 – 74
60 – 68
65 – 76

0.80

No Hx

Male (n=26)
Female(n=40)
Overall(n=66)

2.6
7.2
5.3

1.8 – 3.5
5.0 – 9.4
3.9 – 6.8

0.06

74.0
66.3
66.1

67 – 80
63 – 70
63 – 69

0.06

Age<65

Male (n=16)
Female(n=16)
Overall(n=32)

3.2
8.5
5.9

2.1 – 4.4
5.1 – 11.0
3.8 – 8.1

0.01
NA*

NA

NA

Male (n=16)
Female (n=35)
Overall(n=52)

2.8
4.1
3.8

1.6 – 3.9
2.9 – 5.3
2.8 – 4.7

0.07

5.3

3.9 – 6.6
NA: Not Applicable

Age>65

Overall Survival

*
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Female Hormones and Survival
To assess the affect of an altered female hormonal milieu the following three variables
were analyzed: (1) history of hysterectomy, (2) diagnosis of other cancers which disrupt the
female hormone production (e.g. cervical carcinoma, ovarian carcinoma, or breast cancer), and
(3) positive history of hormone replacement therapy (HRT). Out of 51 female patients in the
study sample 24 had undergone hysterectomies, 11 had other types of female cancers, and 7 had
positive history of HRT. Survival analysis of female patients using Kaplan Meier life tables is
shown in Table 5. Only the patients who had undergone hysterectomies showed a significant
difference in survival when compared to patients who had not. Women who had undergone the
procedure survived better than those who had not (5.1 yrs vs. 3.3 yrs, p-value=0.02). A survival
curve highlighting the difference in cumulative survival between patients who had a history of
hysterectomy and those who did not is shown in Figure 4.
Table 5.
Mean Survival for Female Patients with Respect to Variables Affecting Hormonal Milieu
Variable

Average Survival time
[in Years]

p-value

(95%CI) [in Years]

HRT
No HRT

5.5
6.5

0.80

0.0 – 11.5
4.6 – 08.6

Other cancers
No other cancers

6.4
6.5

0.90

2.5 – 10.1
4.3 – 08.6

Hyst*
No Hyst

7.1
4.2

0.02

4.3 – 09.9
3.0 – 05.3

*

Hyst: Hysterectomy
Survival analysis performed using Kaplan Meier life tables
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Survival Functions
Hyst

1.0

1
2
1-censored
2-censored

Cum Survival

0.8

0.6

0.4

0.2

0.0
0.0

5.0

10.0

15.0

20.0

yrs after Dx

Figure 4. Survival Curve Depicting Differences in Survival by History of Hysterectomy
Hyst 1: hysterectomy performed
Hyst 2: hysterectomy not performed
Survival curve plotted using Kaplan Meier life tables

Comparison Of Patients Diagnosed Before 1999 With Those Diagnosed After 1999
This study group had almost equal number of patients who had been diagnosed after May
1999 as before May 1999 (Table 6). The follow-up period for patients diagnosed before 1999
was much longer than those diagnosed after May 1999, as would be expected for a study
comprising subjects from 1988 - 2005.

39

Table 6.
Descriptive Statistics for Year of Diagnosis
Year of diagnosis

Frequency (n)

Before May 1999

42

Percentage
(%)
50.6

After May 1999

41

49.4

Avg. years of
follow-up
7.8
3.4

The results of the survival analysis and ANOVA (to assess mean age at diagnosis) are
tabulated in Table 7. The mean age at diagnosis after 1999 was higher than for patients
diagnosed before 1999 (68 yrs. vs. 64 yrs). This trend was unchanged after stratification by
gender. For this patient series, the patients diagnosed before 1999 showed a survival advantage
over those diagnosed after 1999 (6 yrs vs. 4.4 yrs). In both the cases (i.e. before and after May
1999) survival was significantly better for female patients as compared to their male counterparts.
The lower mean age at diagnosis in patients diagnosed before 1999 can be the confounding
factor that contributed to longer mean survival for these patients.
Table 7.
Mean Survival of Patients Diagnosed Before 1999 and After 1999
Variable

Survival
(yrs)

95% CI
(yrs)

p-value

Age
(yrs)

95% CI
(yrs)

p-value

Before

Male
Female
Total

3.7
7.0
6.0

2.3 – 5.1
4.4 – 9.6
5.2 – 8.0

0.2

60
65
64

53 – 76
61 – 69
60 – 74

0.4

After

Male
Female
Total

2.5
5.8
4.4

1.6 – 3.3
3.1 – 8.6
2.7 – 6.2

0.06

63
67
68

58 – 68
62 – 71
63 – 72

0.3
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Comparison Of Study Results with KCR and SEER Datasets
The findings from this study group were compared to analyses performed using the KCR
and SEER datasets. The results of this comparison are presented in Table 8. Women constituted
61% of study group, for the state data this percentage was almost 55%, and SEER dataset
constituted 53.8% female cases. The mean age at diagnosis for study sample was 67 yrs, which is
similar to the pattern noticed in KCR and SEER data (66.4 yrs and 67.1 respectively). Women
were older (68.5) than men (64.7) for the study group. This is in contrast to the KY and SEER
datasets where women were diagnosed younger than men. The mean length of survival after
diagnosis was 5.3 years which was significantly higher than both the state and national datasets
(4.0 yrs for KY and 3.5 yrs for SEER). In the study group women presented with a longer
survival than men (6.5 yrs vs. 2.8 yrs), this is in contrast with the KCR dataset where this
difference in not significant (4.1 vs. 3.9); the SEER dataset on the other hand also presented an
increased survival in women compared to men (3.9 yrs vs. 3.4 yrs). As far as increase in survival
after reclassification in 1999 was concerned, the study sample suggested a survival advantage for
patients diagnosed before 1999. This result could be confounded by younger age of patients
diagnosed before 1999 in this patient group. Comparison of survival before and after 1999 could
not be performed for the other two datasets because of lack of such information.
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Table 8.
Comparison of Regional, State and National Data with Respect to Proportion of Female Patients,
Age at Diagnosis and Survival Time

years
Total number (N)
Women (%)

Study Sample

KCR

SEER

1988-2005
(16 yrs)

1996-2000
( 5yrs)

1973-1998
(25 yrs)

83

350

8777

61%

55%

53.8%

Avg. age at
Dx*
(with 95%
CI)

Men
Women
Overall

64.7 (61.0-66.0)
68.5 (65.8-72.0)
67.1 (63.0-71.5)

67.0 (65.6-73.0)
64.3 (58.0-66.7)
66.4 ( 62.5-70.8)

67.8 (63.1-69.5)
65.2 (64.4-70.4)
67.1 (65.4-72.1)

Avg. survival
(with 95%
CI)

Men
Women
Overall

3.0 (2.2-3.8)
6.5 (4.6-8.4)
5.3 (3.9-6.6)

3.9 (3.6-4.2)
4.1 (3.7-4.5)
4.0 (3.7-4.2)

3.4 (3.0-3.8)
3.9 (3.2- 4.1)
3.5 (2.2-3.8)

*

Dx: Diagnosis
Analysis performed using Kaplan Meier survival analysis and ANOVA

Further comparison was made between the study group and the KCR data using Kaplan
Meier survival analysis as shown in Table 9. Patients who had undergone hysterectomies in the
study sample were compared to pre-and post-menopausal women in the KCR dataset. The results
indicated that women who had undergone hysterectomies survived longer than women who had
not (7.1 yrs vs. 4.3), while women who were pre-menopausal seemed to be doing better than
those who were post-menopausal (4.1 yrs vs. 3.5 yrs). The menopause status data were not
available from the SEER dataset. Patients in this study group who lived in urban settings
survived better than those in rural settings (4.2 yrs vs. 2.6 yrs); however, there was no significant
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difference in the overall survival with respect to the KCR dataset. After stratifying for gender the
effect seemed to be more pronounced in men (3.4 yrs vs. 1.9 yrs) in the study group, but no
significant differences were seen in the KCR data.

Table 9.
Mean Survival of Study Sample and State Data by Variables of Interest
Study Sample
Survival in yrs
(95%CI)

KCR
Survival in yrs
(95% CI)

Male

Rural
Urban
Overall

2.4 (1.0-3.0)
3.6 (2.9-4.8)
2.8 (2.2-3.8)

3.9 (3.5-4.3)
3.9(3.4-4.3)
3.9 (3.6-4.2)

Women

Rural
Urban
Overall

4.2 (2.5-5.0)
6.9 (4.5-5.8)
6.5 (4.6-8.4)

3.7 (3.1-4.2)
4.5 (4.0-5.0)
4.1 (3.7-4.5)

Women

No Meno#
Meno

NA*

4.1 (3.7-4.6)
3.5 (2.6- 4.0)

7.1 (4.3 – 9.9)
4.2 (3.0 – 5.3)

NA*

Hyst
No Hyst
*

NA: Data Not Available, # Meno: Menopause
Analysis performed using Kaplan Meier life tables.
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CHAPTER 5
DISCUSSION
The main objective of this research was to highlight the differences in survival between
the two genders among patients with BAC. The results of this research indicated that women had
an overall survival benefit over men; this survival advantage was observed even after stratifying
for age, residential location, family history, and year of diagnosis. This research shows that male
patients are at a five-times higher risk of dying from their BAC than female patients.
Furthermore, the results of this series of patients showed that the survival advantage was more
obvious for 5-year survival than for 1-year survival as noticed by previous authors. Among nonsmokers, females constituted a considerable proportion of the BAC patients. Comparing the three
datasets (study, KCR, SEER), similar trends were noticed in terms of the gender ratio. All three
datasets (study sample, KCR and SEER) presented with female patients constituting more than
half of the patients (61%, 55% and 54% respectively).
Furthermore, the mean age-at-diagnosis for this study showed an older age for women
compared to men contrasting with the state KCR and national SEER data, where women
presented younger. The reason for older age of women at diagnosis cannot be fully explained. A
possible reason for later diagnosis could be higher average age of women in the two regions than
men (The US Census Bureau, American Community Survey Data Profile, 2003). At the same
time the average survival was longer in women than men and even though similar trends were
seen in KCR and SEER data, this observation was more pronounced in this study population.
BAC is a rare form of lung cancer; our study group of 83 patients represented a reasonable subgroup to use for comparison purposes as there were only 350 patients reported in the whole state
of KY during a comparable time period. This research also showed that the patients who were
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alive at the time of data retrieval were younger at the time of diagnosis than patients who died of
the disease (64 yrs vs. 67 yrs), indicating that younger age-at-diagnosis is a predictor of good
prognosis.
Earlier literature reports the younger age-at-diagnosis in women compared to men as one
of the possible contributors to longer survival for women (Edgerton et al., 1981; Leno et al.,
2005; Page et al., 2000), but this study indicates that the survival advantage in women compared
to men is not just a consequence of age. After stratifying survival by age (older than 65 and
younger than 65) survival is found to be better for younger patients than older patients. This
effect was more pronounced after stratifying for gender. These findings suggest that female
gender is a better prognostic factor for survival than male even after taking the effect of age into
account.
This research further indicated that the patients who had a family history for lung cancer
presented older and with poorer prognosis than patients with no family history. This finding was
in contrast with trends reported in literature (as cited in Cote et al., 2005) which suggests that
patients with family history presented younger but still had poorer prognosis.

Association Between Smoking History and Survival
Classically, smoking is associated with poorer prognosis when smokers are compared to
non-smokers. This trend is suspected to contribute a part of the survival advantage that nonsmoker BAC patients have over smokers (Radzikowska et al., 2002). Non-smokers in this study
group did not show a significant survival advantage over smokers.
In a study assessing outcomes for histological sub-types of lung cancer, it is very
important to analyze the effect of smoking as an etiological agent. Because of the widespread
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prevalence of smoking, it becomes very difficult to make such assessments. This study faced
similar limitations while analyzing the effect of smoking on survival. There were only three male
patients who were non-smokers, so it was not possible to make gender distinction on the effects
of smoking. Furthermore, the data included inconsistent coding formats with respect to smoking
history. Also, no information was gathered to assess the extent of environmental smoking history
(e.g. smoking history of either spouse or other family members).
Recent studies on BAC indicate that the proportion of non-smoker patients of either sex
is increasing (Leno et al., 2005). BAC is beginning to gain distinction as a female, non-smoker’s
lung cancer (as cited by Devasa et al., 2005). It would seem very important to establish the true
burden of smoking as an etiology including under-reported environmental smoking before such
terminology could be appropriately applied. A good study design to make such assessment could
be inspired by the one used by Kit et al. in China who eliminated the confounding effect posed
by smoking by conducting their study in non-smoking women (as cited by Page et al., 2000).

The Effect of Geographical Location on Survival
BAC patients in this study who resided in urban areas were significantly younger than
those from rural areas. This association with survival was seen in both sexes. Similar trends were
noticed in the KCR sample, although not to the same extent as the study group. According to the
KCR dataset the survival advantage for urban patients was better in women compared to men.
Female urban patients also showed this advantage over rural female patients, but no significant
changes were seen for men with BAC in the KCR dataset.
The exact reason for this association by location of residence is difficult to ascertain until
further research is conducted. Access-to-care issues for rural populations can be a reason for
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such finding. Another reason for better survival reported from the Louisville registries could be
because of both registries at Louisville being associated with metropolitan, tertiary care hospitals.
Such facilities may be better equipped with infrastructure enabling early diagnosis and proactive
treatment when compared to the community hospital configuration at Western Baptist hospital in
Paducah. Early age-at-diagnosis may contribute to better survival of urban patients compared to
rural patients. A possible contributor to older age-at-diagnosis of patients living in Paducah
compared to Louisville could also be the older mean age of residents in Paducah as compared to
Louisville (38 yrs vs. 35 yrs) (The US Census Bureau, American Community Survey Data
Profile, 2003).

Association Between Female Hormones And Survival
One of the objectives of this research was to assess the effects of estrogen on survival of
lung cancer. We examined various variables that can have a possible effect on estrogen
production in the body e.g., hysterectomy, HRT, and other cancers such as breast, ovarian, and
cervical. Of these variables, only hysterectomy showed a significant effect on survival. There
was no difference in mean age-at-diagnosis between the patients who had undergone
hysterectomy and those who had not, therefore, suggesting that the patients who underwent
hysterectomy clearly showed a survival advantage over those who had not. After hysterectomy
the estrogen levels in the body decrease. This increase in survival could be because of a decrease
in estrogen levels. More definitive research needs to be performed before any conclusions can be
drawn. To make a similar assessment with the KCR data we compared women who were premenopausal to those who were post-menopausal. Pre-menopausal women showed a distinct
survival advantage over post-menopausal women. A confounder for such observation may be the
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fact that premenopausal group was considerably younger than postmenopausal group.
Estrogen’s affect on lung cancer survival is controversial. Certain studies (Ishibashi et al., 2005)
report it to be associated with poor prognosis and others suggest a protective affect (McDonielsSilvers et al., 2002).

Affect of Reclassification in 1999
This research project also attempted to discern whether or not reclassification in 1999
contributed to an increase in survival of patients with BAC. These study findings indicate that
patients who were diagnosed before 1999 were at a survival advantage when compared to those
who were diagnosed after 1999. This observation could be a result of confounding by age as
patients diagnosed before 1999 were significantly younger than those diagnosed after 1999.
These findings should be interpreted very cautiously as the follow-up period of patients who
were diagnosed after 1999 was also very small in our group compared to the patients who were
diagnosed before 1999. Another confounder in this respect is the 2 year lag that generally exists
between the changes in definition and the implementation by the concerned organizations.
Because the information of the exact year the updated definition was implemented by these
registries is unavailable, these findings cannot be viewed as conclusive.

Limitations
1) One of the biggest limitations of this research is unavailability of data regarding the
size of tumor and extent of metastasis. These two variables are the most important predictors of
the length of survival in BAC patients (Ebright et al., 2002).
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2) An important consideration is the suitability of the study group as a representative of
the population of the two counties. African-Americans were underrepresented in this sample. In
both these counties African Americans represents 28-33% of the population (The US Census
Bureau, American Community Survey Data, 2003) while this sample consisted of only 8.4%
African American patients.
3) The data do not provide any information on environmental smoking, which is an
important consideration when assessing any lung cancer relationship especially one that presents
a lower risk association with respect to smoking. The reason that this cancer type presents with a
lower risk with smoking could be an artifact noticed because of under-reported environmental
smoking.
4) This study used hospital records as tools of data retrieval. This can result in possible
information bias. For example, the records lacked consistent method of coding for smoking
status [e.g., not recorded, versus not assessed, versus refused, etc.].

Recommendations for Future Research
BAC is the most common lung cancer cell type in females (smokers or non-smokers) and
in non smoking males. Its incidence has been increasing in younger cohorts of males and females
until very recent years. Changes in classification and in pathological techniques can account for
some of this increase. In females and non-smoker males, the increase could be partly because of
a detection bias in former studies. Nevertheless, successive cohorts over time seem more likely
to develop adenocarcinoma and less likely to develop squamous cell carcinoma. This probably
represents a true increase in incidence of BAC. An explanation for this should be sought in
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studies on detailed smoking history and passive smoking exposure, occupational exposure, diet
and cooking, pollution, and other environmental factors (Laskin, 2004).
More research needs to be conducted to establish the exact burden of smoking as a risk
factor for BAC and to explore the other possible causes of BAC in order to establish multi-modal
prevention techniques. A possible direction in this regard may be the exploration of
environmental smoking as a risk for BAC and comparing its relationship to other histologic
categories of lung cancer.
More research needs to be done on differences in BAC outcomes between the genders
and how gender affects the course of the disease. One of the increasingly prominent areas of
research is the role that estrogen plays in this regard and how the differences in the male and
female physiological makeup can be used with respect to newer treatment modalities. Authors
are largely divided on the effects of estrogen (as cited in Ishibashi et al., 2005). Further
investigation needs to be done regarding the role of estrogen in the progression of carcinogenesis
and for the possibility of productive treatment with HRT.
Furthermore, no research has been performed that has exclusively addressed the possibility
of a different line of treatment for BAC patients (Leno et al., 2005).Various studies over the past
decade have highlighted differences in the epidemiology and demographics of BAC, but very little
work has focused on use of these differences towards improvement of survival (Liu et al., 2000;
Zang & Wynder, 1996). BAC patients are still treated the same way as other adenocarcinoma
patients. Analyses like the one presented here indicate a definitive survival advantage of female
patients over male but no attempts have been made to use this survival advantage by exploring new
treatment methods.
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In conclusion, it can be stated that BAC is the most common lung cancer cell type in
females and a survival advantage exists for female BAC patients as compared to their male
counterparts. And, there is much potential for using this advantage for the improvement of
prognosis of both male and female patients with BAC.
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